Search 

   Glenpharma AB is a small privately owned research spin-off from Pfizer-Pharmacia, formed in Sweden in 2002 to exploit novel technology patented by its founders. 

We offer patented synergistic combinations of biopolymers for 

a) accelerated repair of acute tendon /ligament injuries in human applications ( such as sprained ligaments / tendons in shoulder, elbow, knee, ankle, etc , in both sports injury scenarios and in the elderly ) , or in veterinary indications (e.g. high performance horses) .  The product accelerates healing at least 3 times faster than the normal healing process. 

b) for prevention of unwanted adhesions between tissues after major thoracic, abdominal , fertility or orthopedic surgery. In studies on prevention of difficult adhesions after cardiac surgery, for example, adhesion scores were < 10% of those in control groups.

c) for effective control of acute pain in advanced joint disease (osteo-arthritis (OA)  .  Clinical documentation in advanced OA indicates that onset of pain relief is much faster and of longer duration than current standards for viscosupplementation. 

Each of the above biopolymer "viscous fluid implants" are also ideal drug delivery media for treatment of ancillary complications.

All component biopolymers are well documented APIs, i.e. without the toxicty and other regulatory issues generally associated with "New Chemical Entities".  Glenpharma´s current patent protection covers most major international markets including USA, Europe and P R China.

Glenpharma is primarily seeking Chinese partners for out-licensing within the fields of orthopedics or major surgery.. If neccessary , we can offer contract-manufacturing options in Europe if not available in China. 

Regulaxis SAS is a French biotech company created in 2013 to develop innovative therapies for human clinic based on new synthetic peptides regulating cell growth and differentiation.

Regulaxis is specialized in the regulation of cell proliferation and/or cell differentiation. The potential therapeutic applications covered by our patents are very broad, especially in the areas of joint/bone or nerve cell regeneration, but also in cancer and related metabolic diseases (diabetes, obesity …).
Our mission is to grant licenses of innovative molecules in a pharmaceutical company after completion of phase II clinical proof of concept.

Regulaxis is strategically focused only on high unmet medical needs but has elected as its first priority:
regeneration of articular cartilage using intra-articular injections of its lead candidate REG-O3.

We are rapidly transitioning to an innovation and R&D driven Pharmaceutical company, leveraging our leading manufacturing and commercial capabilities to achieve our mission of “providing today' s patients with medicines of the future“ We have been continuously recognized as one of the “Top 10 Innovative Pharmaceutical Enterprises in China” 1 and “Top 100 Pharmaceutical Manufacturing Enterprises of China”